# Amantadine in Treating Cognitive & Motor Impairments in Adolescents and Adults With Cerebral Palsy

> **NCT04273737** · PHASE4 · TERMINATED · sponsor: **Columbia University** · enrollment: 11 (actual)

## Conditions studied

- Cerebral Palsy

## Interventions

- **DRUG:** Amantadine Hydrochloride

## Key facts

- **NCT ID:** NCT04273737
- **Lead sponsor:** Columbia University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-02-28
- **Primary completion:** 2022-02-22
- **Final completion:** 2022-02-22
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** PI left institution.
- **Last updated:** 2022-05-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04273737

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04273737, "Amantadine in Treating Cognitive & Motor Impairments in Adolescents and Adults With Cerebral Palsy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04273737. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*